marlon perera

Urologic Oncologist | 🇦🇺FRACS (Urology) PhD (UniMelb) Fulbright @AustAmFulbright | @UroOnc alum at @UrologyMSK

[USANZ @USANZUrology]

Following a recent EOI process, @BJUIjournal have announced the new Editor for the BJUI USANZ Supplement. The role will be shared between @drMPerera and A/Prof Matthew Roberts.

We thank the outgoing editor @lawrentschuk for his ten years of service to USANZ and Urology.

[Declan Murphy @declangmurphy]

Ambushed by these two rad oncs @_ShankarSiva @DrAndrewLoblaw Sounded like they were taking me to a surgical technology launch but it was a CyberKNIFE launch! Robotic radio-surgery they say #notarealknife but impressive kit! @drMPerera @davcmed. GU Cast coming soon! @gu_onc

[Shankar Siva @_ShankarSiva]

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence.
🚨Meta-analysis of 43 studies (n=8,119)
⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb!
➡️link https://t.co/VYvAn6kli1

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment

https://t.co/DxvePNnJRX

systematic review and meta-analysis evaluated the diagnostic performance of PSMA PET imaging in detecting local or metastatic disease in 8,119 #ProstateCancer patients experiencing biochemical recurrence (BCR) following radical prostatectomy or radiation therapy. The analysis revealed that PSMA PET positivity rates varied significantly based on prior treatment type, PSA levels, and lesion location, with higher detection rates seen after radiation therapy (92%) compared to prostatectomy (60%). Positivity increased with rising PSA levels, reaching over 90% at PSA >2 ng/ml🧪. Detection was most common in pelvic nodes and local recurrence, while visceral metastases were rare.

Study heterogeneity limits generalizability, but the findings underscore the importance of PSA stratification and highlight PSMA PET’s potential to inform salvage treatment decisions, especially in early recurrence.

@elio_mazzone
@donatocann
@Leo__Quarta
@PellegrinoMD
@GGandaglia
@DrDanielMoon
@RenuEapen
@lawrentschuk
@F_Montorsi
@_ShankarSiva
@DrMHofman
@Albert0Briganti
@drMPerera
@declangmurphy

Ping @Silke_Gillessen @AOmlin
@OncoAlert 🚨
@nataliagandur @bavilima

[UrologyMSK @UrologyMSK]

Now published in @UrolOncol by @UrologyMSK Jonathan Coleman, Paul Russo, @arihakimi et al.:

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors
https://t.co/jy76C0dzqd

[Cristian Udovicich @cristian_udo]

Is there a role for PSMA PET/CT in oligometatastic RCC?
Check out our @JournalofNucMed PEDESTAL study on PSMA-guided metastasis-directed therapy from @PeterMacCC @_ShankarSiva @DrMHofman

🧍33 pts & 60 metastases
🛜 93% radiotherapy
📖Median follow-up> 4y

✅Local control: 94% at 1y, 85% at 3y
✅Freedom from change (or commencement) of systemic therapy: 76% at 1y, 65% at 3y

[Michael Hofman @DrMHofman]

Impact of intraprostatic PSMA SUVmax following prostatectomy: a systematic review and meta-analysis

First publication of 2025 - congrats @davcmed @drMPerera

@BJUIjournal
https://t.co/jqExEUKIva

"Preoperative intraprostatic PSMA SUVmax increases monotonically with higher ISUP Grade Group and pathological tumour stage. Higher SUVmax is associated with reduced BCR-free survival. However, the use of single SUVmax thresholds for clinical decision making is not recommended as variability between studies is high."

[Peter Mac Cancer Centre @PeterMacCC]

Peter Mac has been named Australia's leading #cancer research institute in @australian newspaper's Research 2025 Magazine, and four of our researchers were named as leader in their field.

Read more: https://t.co/XGRPQviadt

[Cristian Udovicich @cristian_udo]

Should prostate RT be an option for all men with de novo mCSPC (high and low volume), despite systemic intensification? Check out our @DrAndrewLoblaw @TheLancet editorial on PEACE-1 RT.

↗️ rPFS and castrate resistance-free survival in low volume
↘️ serious GU AEs regardless of volume

https://t.co/X3WG7dGMcf

[Urologic Oncology @UrolOncol]

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors https://t.co/N0fJqO8W3X

[European Urology @EUplatinum]

Words of Wisdom Wednesday: Re: First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma by Alice Thomson et al

Read the full article here: https://t.co/nkbJZOww8l

#UroSoMe #MedTwitter #EurUrol #WoW #WordsofWisdomWednesday

@Sachinpp_ @lawrentschuk @drMPerera @RenuEapen @declangmurphy

[Marc Diocera @MarcDiocera]

Dr @drMPerera on Sub-stratification of Intermediate Risk #ProstateCancer | “w the same amount of Pattern 4, why does the amount of Pattern 3, dictate mx for GG 2-3 dse?” | #apcc24 @PeterMacCC @MSKCancerCenter

🟩🟩🟩🟩⬜️= GG1
🟥🟥🟩🟩🟩= GG2
🟥🟥🟩🟩⬜️= GG3

[BJU International @BJUIjournal]

August's #CaseOfTheMonth is from the @PeterMacCC: an operative approach to large renal #angiomyolipoma associated with lymphangioleiomyomatosis @JonathanSOBrien @MarcDiocera @declangmurphy @lawrentschuk @PetePocharapong @drMPerera @davidgyorki

https://t.co/qQ5wWUgIVq

[marlon perera @drMPerera]

From GU onc at #EAU24 to GU energy gels at @parismarathon. Paris you’ve been a blast 🇫🇷🥐

[marlon perera @drMPerera]

FAPI PET - Highlighting the promising data on one of the latest PET candidates in RCC

https://t.co/sSGQ9EHtbl

@DrMHofman @_ShankarSiva @cristian_udo @gu_onc #ejnmmi

[@SN_Oncology @SN_Oncology]

Comparison of 18F-based #PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of #prostatecancer — a systematic review and meta-analysis: https://t.co/T0Bb2sNHfh @drMPerera

[Helen OConnell AO @OconnellProf]

#KUA2023 opening session on case with high PSA and one pelvic node - work of ⁦@DrMHofman⁩ ⁦@drMPerera⁩ on role of PSMA recognised ⁦@USANZUrology⁩ ⁦@urologytraining⁩

[UrologyMSK @UrologyMSK]

We are very pleased to announce this year's Virtual Open House for interested SUO Fellowship Applicants. Please join us on November 15th at 7pm EST. RSVP to receive a Zoom link to join us-- https://t.co/5UWKyrvtUQ

[Eur Urol Focus @EurUrolFocus]

Outcomes of Grade Group 2 and 3 PCa on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance

https://t.co/BWMdMdyVRQ

@drMPerera @GhalibJibara @statistishdan @SigridCarlsson @vinlaudonemd @TouijerKarim @rovingatuscap @VickersBiostats @BehfarEhdaieMD

[UrologyMSK @UrologyMSK]

🥇Very exciting day for our Urology team led @easthamja 🥇!!!

https://t.co/hjTtUoDaKJ